<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04598542</url>
  </required_header>
  <id_info>
    <org_study_id>SM04690-OA-16</org_study_id>
    <nct_id>NCT04598542</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers</brief_title>
  <official_title>Open-Label, Parallel-Arm Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Corticosteroid Intra Articular Injection Given 7 Days Before or 7 Days After Lorecivivint Intra-articular Injection Into the Knee of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosplice Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosplice Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label, parallel-arm study to determine if a prior intra-articular&#xD;
      (IA) injection of lorecivivint (LOR) affects the safety, tolerability, and/or&#xD;
      pharmacokinetics (PK) of a subsequent IA injection of the corticosteroid triamcinolone&#xD;
      acetonide (TA) into the same knee, and to determine if a prior IA injection of TA affects the&#xD;
      safety or tolerability of a subsequent IA injection of LOR into the same knee.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Actual">December 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of LOR</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-last of LOR</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration profiles of LOR</measure>
    <time_frame>0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of TA</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-last of TA</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration profiles of TA</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Drug-Drug Interaction</condition>
  <arm_group>
    <arm_group_label>TA injection followed by LOR injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IA injection of TA into the right knee, followed by IA injection of LOR into the same knee 7 days later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LOR injection followed by TA injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IA injection of LOR into the right knee, followed by IA injection of TA into the same knee 7 days later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorecivivint (LOR)</intervention_name>
    <description>0.07 mg</description>
    <arm_group_label>LOR injection followed by TA injection</arm_group_label>
    <arm_group_label>TA injection followed by LOR injection</arm_group_label>
    <other_name>SM04690</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone acetonide (TA)</intervention_name>
    <description>40 mg</description>
    <arm_group_label>LOR injection followed by TA injection</arm_group_label>
    <arm_group_label>TA injection followed by LOR injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Males and females between 18 and 55 years of age, inclusive, in general good health&#xD;
&#xD;
          2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at Screening&#xD;
&#xD;
          3. Negative drug test for amphetamine, cocaine, methadone, opiates, phencyclidine (PCP),&#xD;
             barbiturates, benzodiazepines, tricyclic antidepressants, and marijuana&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women, breastfeeding women, and women who are not post-menopausal (defined as&#xD;
             12 months with no menses without an alternative medical cause) or permanently&#xD;
             surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral&#xD;
             oophorectomy) who have a positive or indeterminate pregnancy test result at the&#xD;
             Screening Visit or Day -1&#xD;
&#xD;
          2. Women who are not post-menopausal or permanently surgically sterile who are sexually&#xD;
             active, and who are not willing to use birth control during the study period&#xD;
&#xD;
          3. Men who are sexually active and of reproductive potential, who have partners who are&#xD;
             capable of becoming pregnant, and who are not willing to use birth control during the&#xD;
             study period&#xD;
&#xD;
          4. Any chronic medical condition that requires medication&#xD;
&#xD;
          5. Any history of IA injection, surgery (e.g., arthroscopy), infection, major orthopedic&#xD;
             injury, or inflammatory rheumatic diseases (e.g., rheumatoid arthritis, gout,&#xD;
             pseudogout) of either knee&#xD;
&#xD;
          6. Any contraindications for an IA injection in the right knee in the opinion of the&#xD;
             Investigator&#xD;
&#xD;
          7. Previous treatment with lorecivivint (LOR)&#xD;
&#xD;
          8. Treatment with any glucocorticoids (oral, intravenous, intramuscular, IA, topical, or&#xD;
             inhaled) within 12 weeks before Day 1&#xD;
&#xD;
          9. Consumption of grapefruit, grapefruit juice, Seville oranges, or vegetables from the&#xD;
             mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi,&#xD;
             brussels sprouts) within 10 days before Day 1&#xD;
&#xD;
         10. Known hypersensitivity to triamcinolone acetonide (TA)&#xD;
&#xD;
         11. Significant blood loss (&gt; 500 mL) or donation of blood within 30 days of screening&#xD;
&#xD;
         12. Regular use of nicotine-containing products, including, but not limited to,&#xD;
             cigarettes, e-cigarettes, or nicotine gum or patches&#xD;
&#xD;
         13. Any condition, that, in the opinion of the Investigator, constitutes a risk or&#xD;
             contraindication for participation in the study or that could interfere with the study&#xD;
             objectives, conduct, or evaluation&#xD;
&#xD;
         14. Estimated glomerular filtration rate (eGFR) of &lt; 60 mL/min/1.73 m2, calculated using&#xD;
             the Modification of Diet in Renal Disease (MDRD) equation at the Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Biosplice Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lorecivivint</keyword>
  <keyword>triamcinolone acetonide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Lorecivivint</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

